TCM
ESPR

Tenor Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Tenor Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-157,732
Closed -$251K – 423
2023
Q1 		$251K Buy
157,732
+141,721
+885% +$732K 0.01% 240
2022
Q4 		$99.7K Sell
16,011
-169,827
-91% -$1.21M ﹤0.01% 346
2022
Q3 		$1.25M Hold
185,838
– – 0.03% 341
2022
Q2 		$1.18M Hold
185,838
– – 0.03% 361
2022
Q1 		$862K Hold
185,838
– – 0.02% 432
2021
Q4 		$929K Buy
+185,838
New +$1.49M 0.02% 434

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Tenor Capital Management's ESPR Position: Q2 2023 in Review

Tenor Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2023, closing a stake of 157,732 shares — an estimated $251K sold.

Tenor Capital Management first reported a position in ESPR in Q4 2021 and held it in 6 quarters. The position peaked at $1.25M in Q3 2022. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

  • Tenor Capital Management reported no remaining Esperion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Tenor Capital Management sold 157,732 Esperion Therapeutics shares in Q2 2023, an estimated $251K.
  • Tenor Capital Management first reported a position in Esperion Therapeutics in Q4 2021 and held it in 6 quarters.
  • Tenor Capital Management's Esperion Therapeutics position peaked at $1.25M in Q3 2022.
  • 124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Tenor Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.